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a  b  s  t  r  a  c  t
This  study  investigated  optimizing  the  formulation  parameters  for  encapsulation  of  a model  muci-
nolytic  enzyme,  -chymotrypsin  (-CH),  within  a novel  polymer;  poly(ethylene  glycol)-co-poly(glycerol
adipate-co--pentadecalactone),  PEG-co-(PGA-co-PDL)  which  were  then  applied  to  the  formulation  of
DNase  I. -CH or  DNase  I loaded  microparticles  were  prepared  via  spray  drying  from  double  emul-
sion  (w1/o/w2) utilizing  chloroform  (CHF)  as  the  organic  solvent,  l-leucine  as  a dispersibility  enhancer
and  an  internal  aqueous  phase  (w1) containing  PEG4500  or Pluronic® F-68  (PLF68).  -CH released  from
microparticles  was  investigated  for bioactivity  using  the  azocasein  assay  and  the  mucinolytic  activity  was
assessed  utilizing  the  degradation  of  mucin  suspension  assay.  The  chemical  structure  of  PEG-co-(PGA-co-
PDL)  was  characterized  by 1H NMR  and  FT-IR  with  both  analyses  conﬁrming  PEG incorporated  into  the
polymer  backbone,  and any  unreacted  units  removed.  Optimum  formulation  -CH-CHF/PLF68,  1% pro-
duced  the  highest  bioactivity,  enzyme  encapsulation  (20.08  ± 3.91%),  loading  (22.31  ± 4.34  g/mg),  FPF
(ﬁne  particle  fraction)  (37.63  ± 0.97%);  FPD  (ﬁne  particle  dose)  (179.88  ±  9.43 g), MMAD  (mass  median
aerodynamic  diameter)  (2.95  ±  1.61  m), and  the  mucinolytic  activity  was  equal  to  the  native  non-
encapsulated  enzyme  up to 5 h. DNase  I-CHF/PLF68,  1%  resulted  in  enzyme  encapsulation  (17.44  ± 3.11%),
loading  (19.31  ±  3.27  g/mg)  and  activity  (81.9  ±  2.7%).  The  results  indicate  PEG-co-(PGA-co-PDL)  can  be
considered  as  a  potential  biodegradable  polymer  carrier  for dry powder  inhalation  of  macromolecules
for  treatment  of local  pulmonary  diseases.
© 2012 Published by Elsevier B.V.
1. Introduction24
Recent advances in inhalation therapy have provoked consid-25
erable interest in the development of novel formulations intended26
for pulmonary delivery of macromolecules (Tamber et al., 2005).27
This is primarily due to the lung having a favourable environment28
for delivery of macromolecules, including enzymes, compared to29
the low pH and high protease levels associated with the gastroin-30
testinal tract (Fu et al., 2002). Furthermore, inhalation therapy of31
macromolecules has focused on dry powder inhalers (DPIs) due32
to their many advantages compared to pressurized metered dose33
inhalers (pMDIs) (Seville et al., 2002). Current research towards34
formulating macromolecules for pulmonary delivery has centred35
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mainly upon biodegradable polymers as carrier based controlled 36
release formulations (Kumar Malik et al., 2007), to increase the 37
quantity of macromolecule reaching the site of action and pro- 38
long its residence time in situ, improve in vivo stability, and allow 39
co-localized deposition with other therapeutic agents or helper 40
excipients (i.e. absorption enhancers) (Cryan, 2005). 41
An alternative class of biodegradable polyester, poly(glycerol 42
adipate-co--pentadecalactone), PGA-co-PDL, have shown 43
promise as sustained release carriers for large and small molecular 44
weight compounds (Gaskell et al., 2008; Kallinteri et al., 2005), 45
and the degree of hydrophobicity can be altered by varying 46
the backbone chemistry or attaching chemical moieties to the 47
free hydroxyl groups (Kallinteri et al., 2005). Recently, we have 48
formulated PGA-co-PDL as a microparticle carrier for pulmonary 49
delivery (Tawfeek et al., 2011) with small aerodynamic diameters 50
(≤3.50 m)  (MMAD, diameter at which 50% of the particles by 51
mass are larger and 50% are smaller than aerodynamic diameter 52
(dae ≤ 4.6 m))  to direct particles to the lung periphery for treat- 53
ment of diseases. For example, in cystic ﬁbrosis, the microparticle 54
0378-5173/$ – see front matter ©  2012 Published by Elsevier B.V.
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formulations delivered via DPIs should possess aerodynamic55
diameters be within 1–5 m micron range (Westerman et al.,56
2007).57
Many enzymes are not stable in phosphate buffered saline58
(PBS) pH 7.4 at 37 ◦C, where chemical degradation (cleavage,59
oxidation, reduction etc.) and physical changes (conformational,60
aggregation and adsorption) on surfaces have been reported (Jiang61
et al., 2002). Moreover, enzyme aggregation may  lead to incom-62
plete release from microparticles (Jiang et al., 2002). For example,63
octreotide showed a slower non-complete release in acetate buffer64
with increasing ionic saline strength and PBS buffer (Bodmer65
et al., 1992), while another luteinizing hormone-releasing hor-66
mone (LHRH) analogue, orntide, showed nearly complete release in67
acetate buffer, but not in phosphate buffer (Kostanski et al., 2000).68
Furthermore, exposure of enzymes to organic solvents, sonication69
and mechanical shear forces during particle preparation results70
in the disruption of the three dimensional structure required to71
maintain their activity leading to complete inhibition of biological72
activity (Perez-Rodriguez et al., 2003).73
Different strategies have been adopted to minimize such prob-74
lems of protein and peptide inactivation, such as, increasing75
protein concentration during emulsiﬁcation (Cleland and Jones,76
1996; Perez and Griebenow, 2001), selection of solvent used in77
microparticle preparation (Castellanos and Griebenow, 2003) and78
incorporating amphipathic excipients (i.e. rat serum albumin),79
which competes with therapeutic protein for the interface between80
organic and aqueous phase (Srinivasan et al., 2005). Moreover,81
surfactants such as Tween 20, 80 (Cleland and Jones, 1996) and82
Pluronic® F68 (Blanco and Alonso, 1998) represent another group83
of amphipathic excipients, which can be applied to these systems.84
Another approach to prevent interface induced protein denatur-85
ation and aggregation is the addition of polyol or sugar excipients86
in the aqueous phase during preparation (Cleland and Jones, 1996;87
Perez and Griebenow, 2001). Poly(ethylene glycol) (PEG) has been88
studied as an emulsiﬁer to decrease aggregate formation of -CH89
loaded poly (lactic-co-glycolic acid) (PLGA) microspheres prepared90
by a soild-in-oil-in-water (s/o/w) technique (Castellanos et al.,91
2005).92
The aim of the current investigation was to optimize the for-93
mulation and delivery of -CH as a model enzyme being highly94
sensitive to unfolding and formulation conditions, via DPIs to95
the lungs using novel biodegradable carrier PEG-co-(PGA-co-PDL).96
PEG was incorporated into the polymer backbone to render the97
particles less susceptible to phagocytosis (Gref et al., 1994) and98
decrease polymer hydrophobicity making the particles more suit-99
able for lung delivery (Fu et al., 2002). In addition, PEG4500 and100
Pluronic® F68 (PLF68) were incorporated in the internal aque-101
ous phase (w1) of the double emulsion in an attempt to prevent102
emulsiﬁcation-induced denaturation and aggregation of -CH.103
Different formulations were prepared by spray drying directly104
from a double emulsion (w1/o/w2), with l-leucine incorporated105
to enhance the dispersibility of the prepared dry particles within106
the respirable size range (Tawfeek et al., 2011) and investigated107
for their encapsulation efﬁciency, enzyme loading, particle size,108
zeta-potential, in vitro release, bioactivity, morphology, aerosoliza-109
tion performance, toxicity and mucinolytic activity. The optimum110
formulation parameters were then used to encapsulate deoxyri-111
bonuclease  I (DNase I) within PEG-co-(PGA-co-PDL) microparticles.112
2. Materials and methods113
2.1. Materials114
Novozyme 435 (a lipase from Candida antarctica immo-115
bilized on a microporous acrylic resin) was purchased from116
Biocatalytics, USA. Glycerol, -pentadecalactone (PDL), PEG (MWs 117
400, 1500 and 4500), -CH (from bovine pancreas, type II), mucin 118
(from porcine stomach, type II), poly(vinyl alcohol) (PVA, MW 119
9-10K, 80%), l-leucine, azocasein, trichloroacetic acid (TCA), RPMI- 120
1640 medium with l-glutamine and sodium hydrogen carbonate 121
(NaHCO3), (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 122
bromide (MTT), ammonium persulphate (APS), TEMED, gelatin, iso- 123
butanol, bromophenol blue, trisma base, glycine, sodium dodecyl 124
sulfate (SDS), colloidal coomassie blue, tris hydrochloride, sodium 125
chloride, calcium chloride, methyl green, bovine serum albumin, 126
thimerosal, Tween 20, and deoxyribonucleic acid (DNA) from 127
salmon testes were all obtained from Sigma–Aldrich, UK. DNase 128
I was obtained from Roche. Chloroform (CHF), dichloromethane 129
(DCM), sodium hydroxide and N-[2-hydroxyethyl]piperazine-N′- 130
[2-ethanesulphonic acid] (HEPES) were purchased from BDH 131
laboratory supplies, UK. Tetrahydrofuran (THF), 75 cm2/tissue cul- 132
ture ﬂask with vented cap (IWAKI brand), 24-well tissue culture 133
plates, 96-well ﬂat bottom plates, antibiotic/antimycotic solu- 134
tion (100×) was purchased from Fisher Scientiﬁc, UK. Phosphate 135
buffered saline tablets (PBS), pH 7.4, were obtained from Oxoid, 136
UK. Divinyl adipate (DVA) was obtained from Fluorochem, UK and 137
PLF68 was  a gift from BASF Corp., USA. Foetal calf serum heat 138
inactivated was  purchased from Biosera, UK. Proto Gel, proto gel 139
resolving buffer, proto gel stacking buffer was purchased from 140
National Diagnostics, USA. Mini-protean tetra electrophoresis sys- 141
tem was purchased from BioRad Laboratories, UK. Human bronchial 142
epithelial (16HBE14o-) cells were produced by Dr Dieter Gruenert 143
from the California Paciﬁc Medical Center, University of California, 144
San Francisco, USA. 145
2.2. Polymer synthesis 146
PEG-co-(PGA-co-PDL) was  synthesized by a combination 147
of enzyme catalyzed polycondensation and ring opening co- 148
polymerization reactions for producing PGA-co-PDL using methods 149
modiﬁed from that as described by Thompson et al. (2006) and 150
He et al. (2003).  Brieﬂy, PEG (0.0005 mol, 1500 Da), and the 151
monomers, glycerol (0.05 mol), divinyl adipate (DVA) (0.05 mol), 152
and -pentadecalactone (PDL) (0.05 mol), were added to the reac- 153
tion medium (THF) prior to addition of novozyme 435 (1 g) and 154
the reaction allowed to proceed for 24 h. Upon completion, 300 ml  155
of DCM was  added and the enzyme was removed by Buchner ﬁl- 156
tration. The solvent was  removed by rotary evaporation and the 157
molten polymer re-dissolved in the minimum amount of DCM. 158
Methanol (100 ml)  was added and the mixture agitated to precip- 159
itate the polymer leaving the unreacted components in solution. 160
The solid polymer was obtained by ﬁltration and air dried before 161
storing over molecular sieves. The synthesized co-polymer was 162
characterized by gel permeation chromatography, GPC (Viscotek 163
TDA Model 300 using OmniSEC3 operating software), calibrated 164
with polystyrene standards (polystyrene standards kit, Supelco, 165
USA). FT-IR spectra were obtained using a Perkin Elmer Spectrum 166
BX spectrometer ﬁtted with a PIKE technologies miracle sampling 167
accessory and using Spectrum v5.0.1 for data processing. 1H NMR  168
spectroscopy was performed using a Bruker AVANCE 300, inverse 169
probe with B-ACS 60 and autosampler with gradient chemming 170
(Thompson et al., 2006). 171
2.3. Effect of release media on the bioactivity of ˛-CH 172
Native enzyme (-CH) (10 mg)  was added to different freshly 173
prepared release media (PBS pH 7.4, distilled water pH 7.5, aqueous 174
1%w/v PLF68 and aqueous 1% w/v  PEG 400, pH 7.15) and incubated 175
for 24 h at 37 ± 0.5 ◦C in an orbital shaker (IKA KS 130) at 250 rpm. 176
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The concentration and the bioactive fraction of the enzyme were177
determined by the following tests:-178
(A) The total enzyme content in the samples was determined179
using spectrophotometry at 282 nm (UV–vis spectrophotome-180
ter Lambda 40, Perkin Elmer).181
(B) Enzyme bioactivity (expressed as bioactive fraction) was182
determined by measuring the proteolytic activity of -CH183
using a chromogenic based technique, the azocasein assay, as184
described by Gaskell et al. (2008) and Jesse and Rudolph (1947).185
The bioactive fraction was calculated as the ratio of enzyme186
concentration recorded from the azocasein test to the enzyme187
concentration obtained from UV spectrophotometeric analysis188
at 0 h (the bioactivity of enzyme just after preparation) and 24 h189
(the bioactivity of enzyme after release from microparticles).190
(C) SDS-PAGE zymography was employed to identify the proteo-191
lytic activity of -CH separated in polyacrylamide gel using192
gelatin as the substrate under non reducing conditions (Kleiner193
and Stetlerstevenson, 1994). SDS-PAGE zymography gels were194
prepared as previously reported (Kleiner and Stetlerstevenson,195
1994). Samples were prepared by mixing 30 l of either non-196
encapsulated native enzyme (control) or enzyme released from197
microparticles before and after 24 h incubation in aqueous 1%198
w/v PLF68 with 30 l sample buffer (10 ml  glycerol, 1 g SDS,199
4 ml  Tris–HCl 1 M pH 6.8, 0.1% w/v bromophenol blue, 50 ml200
deionised water). Samples were loaded onto the gels placed201
within mini-protean tetra electrophoresis system and elec-202
trophoresis was conducted by applying a constant current of203
26 mA  per gel for approximately 60 min, followed by incuba-204
tion at room temperature (25 ◦C) in 50 mM Tris–HCl buffer,205
pH 7.4 (121.14 g Tris base, 69.1 ml  conc. HCl and 824 ml  dis-206
tilled water) with 2.5% Triton X-100, to remove SDS, followed207
by washing with distilled water. The gels were then incu-208
bated at 37 ◦C overnight in enzyme buffer (30 mM Tris–HCl pH209
7.4, 200 mM NaCl, 10 mM CaCl2·2H2O) followed by colloidal210
coomassie blue staining for 90 min  and then de-staining in dis-211
tilled water for 2 h. Evidence of -CH activity was demonstrated212
by the absence of staining in areas where the gelatin substrate213
had been degraded.214
2.4. Microparticle preparation215
Microparticles were prepared by spray drying directly from a216
double emulsion (w1/o/w2) as reported by Tawfeek et al. (2011)217
with modiﬁcations. 50 mg  -CH was dissolved in 1.5 ml  distilled218
water (w1) containing different concentrations (% w/v) of PLF68219
(1 and 3.4) or PEG4500 (1, 3.4 and 6.7). The enzyme solutions220
were homogenized (IKA yellowline DI 25 basic at 8000 rpm for221
1 min) in 15 ml  DCM or CHF containing 450 mg  polymer to form222
the ﬁrst w1/o emulsion. This was then added to a second aque-223
ous phase (w2) (150 ml  distilled water containing 1% w/v  PVA as224
an emulsiﬁer and l-leucine (1.5% w/w of polymer weight) as a dis-225
persing agent), under moderate stirring conditions (silverson L5RT226
mixer, 2000 rpm at room temperature, 25 ◦C) to form the w1/o/w2227
double emulsion. The formulations will be represented within228
the text as: DCM alone, CHF alone, [CHF/PLF68, 1%], [CHF/PLF68,229
3.4%], [CHF/PEG4500, 1%], [CHF/PEG4500, 3.4%], [CHF/PEG4500,230
6.7%]. Microparticles incorporating DNase I were prepared using231
CHF/PLF68, 1%.232
2.5. Microparticle characterization233
2.5.1. Yield, encapsulation efﬁciency and enzyme loading234
Spray dried PEG-co-(PGA-co-PDL) microparticles yields were235
quantiﬁed as the percentage mass obtained compared with the236
anticipated total powder yields. All analyses in the manuscript were237
conducted in triplicate unless otherwise speciﬁed. The enzyme 238
loading (EL) and percentage encapsulation efﬁciency (EE) were cal- 239
culated using Eqs. (1) and (2):  240
EL = weight of -CH in microparticles
microparticles sample weight
(1) 241
EL (%) = actual weight of-CH in sample
theoretical weight of -CH
× 100 (2) 242
Brieﬂy, 10 mg  of microparticles were weighed and solubilized in 243
a mixture of DCM/water (2:1) to dissolve the polymer and extract 244
the enzyme. The two  phases were separated by centrifugation 245
(5 min  at 16,200 × g, accuspin micro 17) and the aqueous layer ana- 246
lyzed for enzyme content spectrophotometrically at 282 nm. The 247
same procedure was applied for formulations containing DNase I. 248
2.5.2. Particle size, zeta potential, powder density and theoretical 249
aerodynamic diameter 250
Spray dried microparticles were sized using a Zetaplus, 251
Brookhaven Instruments, UK. 100 l of microparticles suspension 252
was diluted to 4 ml  using double distilled water and the measure- 253
ments recorded at 25 ◦C. The zeta potential was determined using 254
the same instrument with 50 l of the suspension added to 2 ml  of 255
distilled water and the measurement was performed using a gold- 256
plated zeta dip probe at 25 ◦C. The theoretical primary aerodynamic 257
diameter (dae) was  calculated using data acquired from geometric 258
particle size (d) and tapped density (p) according to Eq. (3) (Tawfeek 259
et al., 2011). 260
dae = d
√
p
p1
, p1 = 1 g cm−3 (3) 261
2.5.3. Degree of crystallinity and particle morphology 262
The degree of crystallinity for the polymer and spray dried 263
microparticle formulations was determined using differential scan- 264
ning calorimetry (DSC, Perkin Elmer Pyris 1) and the thermal data 265
was determined from the second heating cycle (Thompson et al., 266
2007). Brieﬂy, 3–5 mg  of sample was placed into a hermetically 267
sealed and crimped pan. Samples were purged with nitrogen at 268
20 ml/min and heated at a rate of 20 ◦C/min. Formulations were 269
visualized by scanning electron microscopy (SEM) (FEI – Inspect 270
S Low VAC SEM). Particles were mounted on aluminium stubs 271
(pin stubs, 13 mm)  using an adhesive conductive carbon tab and 272
air dried. Samples were coated with gold (EmiTech K 550X Gold 273
Sputter Coater, 10–15 nm)  prior to examination at an accelerating 274
voltage of 25 mA for 3 min. 275
2.6. In vitro release testing 276
Brieﬂy, 10 mg  of spray dried microparticles was added to a 277
1.5 ml  microtube containing 1 ml  pre-warmed (37 ± 0.5 ◦C) aque- 278
ous 1% w/v PLF68 release medium and incubated at 37 ◦C in an 279
orbital shaker (IKA KS 130) at 250 rpm over 24 h. The supernatant 280
was collected after centrifugation (5 min  at 16,200 × g, accuspin 281
micro 17) at designated time-points and stored at 2–4 ◦C until fur- 282
ther analysis. The bioactivity of released -CH from the different 283
formulations was  determined at 0 h and after 24 h using the azo- 284
casein assay described above. The enzyme activity of DNase I was  285
determined at 0 h and 24 h using a colorimetric assay performed 286
at room temperature (Sinicropi et al., 1994). Release samples and Q2 287
unprocessed DNase I (100 l) were added to 96-well plate followed 288
by 100 l of DNA-methyl green substrate, and incubated at room 289
temperature for 90 min. The reaction was  quenched with 50 l 290
of EDTA–hydrogen peroxide solution (50 mM)  and the absorption 291
measured at 620 nm.  This was immediately followed by incubation 292
for a further 90 min  before measuring the absorption at 620 nm.  The 293
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difference in absorption was used to calculate the activity of DNase294
I compared to unprocessed DNase I.295
2.7. In vitro aerosolisation investigations296
Aerodynamic particle size distribution was determined using297
next generation impactor (NGI) (Copley Scientiﬁc, Nottingham,298
UK). Microparticle samples (20 ± 0.4 mg)  were manually loaded299
into hydroxypropyl methylcellulose capsules (HPMC size 3) and300
placed in a HandiHaler®. A ﬂow rate of 60 L/min for 4 s was  applied301
using a pump (Copley Scientiﬁc, Nottingham, UK) to deposit the302
particles on the impactor plates which were coated with 1% w/w303
glycerol/methanol solution. Following inhalation all parts of NGI304
were washed with DCM/water (2:1), and analyzed as above. The305
ﬁne particle fraction (%FPF) (deﬁned as the mass of drug deposited306
(dae < 4.6 m),  was expressed as a percentage of the emitted dose.307
The mass median aerodynamic diameter (MMAD) was  calculated308
by plotting cumulative percentage of mass less than stated aerody-309
namic diameter (probability scale) versus aerodynamic diameter310
(log scale). The ﬁne particle dose (FPD) was expressed as the mass311
of drug deposited in the NGI (dae < 4.6 m).312
2.8. Cell viability study313
The effect of microparticle formulations produced using CHF314
alone, optimum formulations [CHF/PL68, 1%] and [CHF/PEG4500,315
1%] (0–5  mg/ml) (n = 6) on the viability of human bronchial epithe-316
lial (16HBE14o-) cells (passage no. 26) were evaluated over 24 h317
using the MTT  assay as previously reported (Tawfeek et al., 2011).318
DMSO (10%) was used as a positive control. The relative cell viability319
(% of control cells) was calculated using Eq. (5):320
Viability (%)  = A − S
CM − S × 100 (5)321
where A is the absorbance of the test substance concentrations, S is322
the absorbance obtained for isopropanol and CM is the absorbance323
obtained for untreated cells incubated with medium (control).324
2.9. Mucinolytic activity325
The mucinolytic activity of -CH was determined using mucin326
as a substrate and monitoring its degradation spectrophotomet-327
rically (400 nm). There are several factors that affect the rate of328
mucin degradation, such as substrate concentration, enzyme con-329
centration, temperature and pH, which were investigated to obtain330
the optimum conditions for the assay (Gaskell et al., 2008). Brieﬂy,331
mucin solution (1.45 ml,  3 mg/ml, 20 mM sodium phosphate buffer,332
pH 7.4) was added into a semi-micro, 2 ml  cuvette and pre-333
incubated under controlled temperature conditions at 37 ± 0.5 ◦C334
for 20 min  to eliminate any temperature variations. 50 l native335
enzyme and 50 l of -CH released from optimum microparticle336
formulation [CHF/PLF68, 1%] and blank microparticles, which had337
been incubated in aqueous 1% w/v PLF68 release medium for dif-338
ferent time intervals (0–24 h), were added to pre-incubated mucin339
solution and mixed by pipette (n = 6). The turbidity of mucin upon340
addition of enzyme was compared with PBS buffer (pH 7.4) as a neg-341
ative control. Samples were analyzed immediately at 400 nm using342
a UV–vis spectrophotometer (Lambda 40, Perkin Elmer) and after343
30 min  incubation at 37 ± 0.5 ◦C. The change in absorbance read-344
ing taken at the two time points was considered as the enzyme’s345
mucinolytic activity.346
2.10. Statistical analysis347
Statistical analysis comparing -CH and DNase I was  performed348
using the paired Student’s t-test with two-tailed comparison.349
All subsequent formulations of [CHF/PEG] and [CHF/PLF68] were 350
compared with control, CHF alone, by a one-way analysis of vari- 351
ance (ANOVA) with Dunnett multiple comparison test. CHF alone, 352
[CHF/PEG] and [CHF/PLF68] formulations and release media were 353
then compared with each other by means of a one-way ANOVA with 354
the Tukey’s comparison test. Differences of p < 0.05 are considered 355
signiﬁcantly different. 356
3. Results and discussion 357
3.1. Characterization of PEG-co-(PGA-co-PDL) 358
The chemical structure of PEG-co-(PGA-co-PDL) (Fig. 1A) was 359
characterized by 1H NMR  and FT-IR. Analysis of the polymer by 360
GPC conﬁrmed a unimodal mass distribution corresponding to a 361
polymer molecular weight of 19.9 kDa with no peaks relating to 362
free PEG (1500 Da), indicating this was  removed by the methanol 363
during the washing stage of polymer synthesis. In conjunction with 364
this data, NMR  and FT-IR analysis (Fig. 1B and C) conﬁrmed that the 365
monomeric units were polymerized with PEG incorporated into the 366
polymer backbone, and any unreacted units were removed. The 367
integrals of the peaks for the CH2 groups of PDL (1.3 ppm, 21H), 368
DVA (2.39 ppm, 4H), glycerol (4.18 ppm, 4H) and PEG (3.67 ppm, 369
1.5H), were used to calculate the actual PEG and monomer ratio 370
in the polymer using a 1H NMR  integration method (Kolhe et al., 371
2004). The actual ratio of PEG-co-(PGA-co-PDL), 0.01:1:1:0.75, was 372
calculated as the ratio of theoretical to actual protons. Additionally, 373
the percentage of PEG in the polymer was calculated as 3.89%, based 374
on the molecular weight ratio of PEG to polymer. 375
3.2. Stabilization of ˛-CH in aqueous release medium 376
Degradation of enzyme resulting in loss of bioactivity can occur 377
either during preparation or in conventional release media (PBS 378
buffer pH 7.4 and distilled water) at 37 ◦C. Hence, in vitro release 379
experiments under physiologically relevant conditions are difﬁcult 380
due to autolysis and protein fragmentation (Perez-Rodriguez et al., 381
2003). PBS (pH 7.4) and distilled water (pH 7.5) resulted in a low 382
bioactive fraction, 0.21 ± 0.06 and 0.12 ± 0.04 respectively, whilst 383
the incorporation of additives, 1% w/v  PEG 400 (pH 7.15) and 1% w/v 384
PLF68 (pH 7.15), to distilled water retained higher enzyme activity, 385
with a bioactive fraction of 0.78 ± 0.09 and 1.02 ± 0.07 respectively 386
after 24 h. Our data indicated the type and/or components of the 387
medium used during in vitro release were inﬂuential, with aqueous 388
1% w/v PLF68 solution, being the optimum to preserve the native 389
enzyme bioactivity during incubation at 37 ◦C over 24 h, compared 390
to the other media (p < 0.05, ANOVA/Tukey’s). Consequently, aque- 391
ous 1% w/v  PLF68 solution was used in all subsequent studies to 392
ensure that any loss in bioactivity was  not associated with the com- 393
position of the release media. The enhanced bioactivity was most 394
likely due to the stabilizing effects of PLF68 resulting in preven- 395
tion of enzyme aggregation and adsorption to hydrophobic surfaces 396
(Blanco and Alonso, 1998). Similar observations were reported 397
(Wolf et al., 2003), indicating the preservation of l-asparaginase 398
activity (100 ± 1.7%) after incubation in aqueous 1% w/v PLF68 399
medium for 24 h. 400
3.3. Microparticle characterization 401
DSC analysis of PEG-co-(PGA-co-PDL) alone produced a crys- 402
talline endothermic peak at 60.66 ◦C with an onset of melting at 403
55.01 ◦C (Fig. 2, Trace A). In contrast, spray dried microparticles 404
CHF alone, [CHF/PLF68, 1%] and [CHF/PEG4500, 1%] exhibited a sig- 405
niﬁcant reduction in the area under the melting endotherm peak, 406
lowered melting point (56.97 ◦C, 57.30 ◦C and 56.95 ◦C respectively) 407
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Fig. 1. (A) Chemical structure of PEG-co-(PGA-co-PDL) polymer, (B) 1H NMR  spectrum of PEG-co-(PGA-co-PDL), and (C) FT-IR spectrum of PEG-co- (PGA-co-PDL).
Fig. 2. DSC thermograms of (A) PEG-co-(PGA-co-PDL) polymer, (B) Spray dried CHF
alone microparticles, (C) spray dried CHF/PLF68, 1% microparticles and (D) spray
dried CHF/PEG4500, 1% microparticles.
and earlier onset of melting (50.84 ◦C, 50.52 ◦C and 49.54 ◦C respec-408
tively) (Fig. 2, Traces B–D) indicating a largely amorphous nature,409
which is characteristic of spray dried products due to the rapid410
drying of droplets (Corrigan, 1995). Consequently, spray drying411
parameters were set to preserve the outlet temperature in the range412
of 44–47 ◦C due to the low melting of PEG-co-(PGA-co-PDL).413
Spray drying the emulsion formulations with l-leucine pro-414
duced dry powders with yields between 66.6 ± 7.1 and 88.8 ± 5.4%415
(Table 1). Microparticles produced using DCM alone resulted416
in signiﬁcantly lower enzyme loading, 13.35 ± 0.45 g/mg par-417
ticles, compared to microparticles produced using CHF alone,418
22.85 ± 2.56 g/mg (p < 0.05, t-test/two-tailed) (Table 1). The419
improvement was related to the low water miscibility of420
CHF (0.8 g/100 ml)  compared to DCM (1.32 g/100 ml). This cor-421
responded to reduced enzyme adsorption at the CHF/water422
interface compared to DCM/water interface (Castellanos et al.,423
2001), resulting in reduced leaching of -CH to the exter-424
nal aqueous phase (w2) during secondary emulsiﬁcation (o/w2425
stage). Furthermore, the reduced partitioning to the external426
aqueous phase (w2) signiﬁcantly enhanced the encapsulation com-427
pared with microparticles produced using DCM alone (p < 0.05,428
t-test/two-tailed). Consequently, CHF was chosen as the organic 429
solvent for preparing the remaining formulations. However, only 430
addition of PEG4500 (1.0 or 3.4% w/v) to the internal phase 431
resulted in an increase in enzyme loading compared to CHF alone 432
(p < 0.05, ANOVA/Dunnett), whereas the addition of PEG4500 (6.7% 433
w/v) resulted in a signiﬁcant reduction to 16.57 ± 0.78 g/mg par- 434
ticles (p < 0.05, ANOVA/Dunnett). A similar trend was observed 435
with encapsulation efﬁciency, which ranged from 12.01 ± 0.40 to 436
25.32 ± 0.64% (Table 1). This has been associated with PLF68 and 437
PEG4500 decreasing the surface tension of -CH solution, leading 438
to reduced protein aggregation and adsorption to hydropho- 439
bic surfaces (Bilati et al., 2005; Blanco and Alonso, 1998). The 440
spray dried yield of DNase I encapsulated microparticles was  441
similar to the formulations of -CH with [CHF/PLF68, 1%]. How- 442
ever, the enzyme loading and encapsulation efﬁciency were 443
lower (p > 0.05, t-test/two-tailed) than the corresponding -CH 444
formulations. 445
All microparticle formulations had a geometrical particle size 446
suitable for pulmonary delivery, with microparticles produced 447
using DCM alone (0.95 ± 0.12 m)  generated signiﬁcantly smaller 448
particles compared to using CHF alone (1.43 ± 0.27 m)  (p < 0.05, 449
t-test/two-tailed) (Table 1). This was associated with CHF hav- 450
ing a higher boiling point compared to DCM, resulting in a 451
slower rate of removal (due to a higher solvency) and greater 452
packing density of the polymer chain during spray drying (Bain 453
et al., 1999). Furthermore, addition of PLF68 or PEG4500 to 454
the internal aqueous phase signiﬁcantly increased the parti- 455
cle size, 1.95 ± 0.14 to 2.66 ± 0.76 m,  compared to CHF alone 456
(1.43 ± 0.27 m)  (p < 0.05, ANOVA/Dunnett) (Table 1). The theoret- 457
ical aerodynamic diameter (dae) for all formulations was  between 458
0.38 ± 0.07 and 1.08 ± 0.37 m.  Moreover, microparticles formed 459
using DCM alone had an anionic surface charge with a zeta poten- 460
tial of −19.67 ± 1.20 mV,  which was  reduced to −14.99 ± 1.46 mV 461
upon changing to CHF, with no signiﬁcant change upon incorpo- 462
ration of PLF68 or PEG4500 (Table 1) (p > 0.05, ANOVA/Dunnett). 463
The negative surface charge demonstrated the anionic nature of the 464
produced microparticles, which may  be associated with incomplete 465
removal of the PVA emulsiﬁer incorporated in the external aqueous 466
phase (w2) of the double emulsion. 467
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Table  1
The physical characteristics of spray dried microparticles (data represent mean ± SD, n = 3).
Formulation Yield (%) EL (g/mg particles) EE (%) Particle size (m) Zeta potential (mV) dae (m)
DCM alone 80.5 ± 5.4 13.35 ± 0.45* 12.01 ± 0.40* 0.95 ± 0.12* −19.67 ± 1.20 0.38 ± 0.07
CHF  alone 66.6 ± 7.1 22.85 ± 2.56 20.57 ± 2.30 1.43 ± 0.27# −14.99 ± 1.46 0.56 ± 0.18
CHF/PLF68, 1% 67.4 ± 4.9 22.31 ± 4.34 20.08 ± 3.91 2.05 ± 0.66 −16.60 ± 0.93 0.87 ± 0.30
CHF/PLF68, 3.4% 68.4 ± 5.5 22.23 ± 1.65 20.01 ± 1.49 2.44 ± 0.13 −17.58 ± 1.98 0.97 ± 0.21
CHF/PEG4500, 1% 83.2 ± 2.6 27.12 ± 3.01 24.41 ± 2.70 2.66 ± 0.76 −14.56 ± 0.50 1.08 ± 0.37
CHF/PEG4500, 3.4% 88.8 ± 5.4 28.13 ± 0.71 25.32 ± 0.64 1.95 ± 0.14 −17.76 ± 1.77 0.78 ± 0.10
CHF/PEG4500, 6.7% 72.8 ± 3.2 16.57 ± 0.78** 14.92 ± 0.70** 2.29 ± 0.35 −15.56 ± 0.93 0.92 ± 0.17
DNase  I CHF/PLF68, 1% 69.1 ± 3.5 19.31 ± 3.27 17.44 ± 3.11 2.21 ± 0.93 −15.50 ± 0.71 1.16 ± 0.23
* DCM alone vs CHF alone (p < 0.05, t-test/two-tailed).
** CHF/PEG4500, 6.7% vs CHF/PLF68, 3.4%, CHF/PEG4500, 1% and CHF/PEG4500, 3.4% (p < 0.05, ANOVA/Tukey’s).
# CHF alone vs CHF/PLF68, 1%, CHF/PLF68, 3.4%, CHF/PEG4500, 1%, CHF/PEG4500, 3.4% and CHF/PEG4500, 6.7% (p < 0.05, ANOVA/Dunnett).
Fig. 3. Scanning electron micrographs of (A) -CH loaded CHF/PLF68, 1% microparticles and (B) CHF/PEG4500, 1%. The scale bar represents 5 m.
The optimum formulations in terms of bioactivity (see Sec-468
tion 3.4,  bioactivity of released enzyme), [CHF/PLF68, 1%] and469
[CHF/PEG4500, 1%], were visualized using SEM (Fig. 3A and B,470
respectively). The spray dried microparticles appeared uniform471
spherical and regular in shape. The smooth surface possibly472
occurred due to rapid microparticle hardening and evaporation473
of CHF rather than solvent partitioning into water. Hence, there474
was limited possibility of water ingress during manufacturing or475
aggregation of particles which often occurs in emulsion solvent476
evaporation techniques. The optimum formulation incorporating477
PLF68, 1% was used to encapsulate DNase I, and had a similar geo-478
metrical particle size, zeta potential and aerodynamic diameter to479
-CH microparticles formulated with [CHF/PLF68, 1%] (p > 0.05, t-480
test/two-tailed) (Table 1).481
3.4. In vitro release and bioactivity of released ˛-CH482
The in vitro release behaviour for all investigated formula-483
tions is represented in Fig. 4A and B up to 5 h as no further484
release of -CH was noted beyond this time point. A signiﬁcantly485
higher enzyme burst release was noted from microparticles pre-486
pared using DCM alone (95.33 ± 5.51%) compared to CHF alone487
(45.70 ± 8.25%) (p < 0.05, t-test/two-tailed). This was due to the low488
boiling point of DCM and faster rate of evaporation, resulting in the489
presence of higher amounts of enzyme on the surface of spray dried490
microparticles.491
Incorporating PLF68 and PEG4500 to the internal phase (w1) of492
double emulsion, [CHF/PLF68, 1%] (41.85 ± 7.34%) and [CHF/PLF68,493
3.4%] (58.12 ± 13.29%), [CHF/PEG4500, 1%] (43.06 ± 6.87%),494
[CHF/PEG4500, 3.4%] (40.15 ± 6.56%), did not signiﬁcantly affect495
the burst release of -CH compared to microparticles produced496
using CHF alone (p > 0.05, ANOVA/Tukey’s). However, a signiﬁ-497
cantly higher burst release was observed with [CHF/PEG4500, 6.7%]498
and [CHF/PLF68, 3.4%] compared to the other formulations (Fig. 4A 499
and B) (p < 0.05, ANOVA/Tukey’s). This was  due to the solubilizing 500
effect of PEG4500 and PLF68 on the polymer matrix, inﬂuencing its 501
plasticity and porosity (Jiang et al., 2002), resulting in more rapid 502
entry of the release medium into the microparticles, eventually 503
accelerating the release of the enzyme (Castellanos et al., 2005; 504
Blanco and Alonso, 1998). It has been reported that complex 505
formations between PLF68 and polyester polymers in organic 506
solution may  be responsible for changes in physicochemical prop- 507
erties of microparticles, such as encapsulation efﬁciency, particle 508
size and release (Blanco and Alonso, 1998). Hence, the release 509
pattern of -CH from microparticles can be tailored by optimizing 510
the additive concentration and selection of organic solvent. The 511
release study indicated that both formulations [CHF/PLF68, 1%] 512
and [CHF/PEG4500, 1%] were considered optimum, with reduced 513
burst release. The formulation of DNase I with [CHF/PLF68, 1%] had 514
a similar release proﬁle to that composed of -CH [CHF/PLF68, 1%], 515
with no signiﬁcant difference in the burst release (25.21 ± 13.29%) 516
(p > 0.05, t-test/two-tailed) (Fig. 4C). 517
Table 2 represents the bioactive fraction of -CH at 0 h and 518
after 24 h release in 1% w/v PLF68 medium. The shear stresses 519
involved in the preparation of microparticles during primary 520
emulsiﬁcation (w1/o stage) and contact with DCM have been 521
recognized as the major cause of -CH aggregation and loss in 522
activity (Castellanos et al., 2005). The results clearly indicated that 523
microparticles prepared using CHF alone signiﬁcantly improved 524
the bioactive fraction compared to particles produced using DCM 525
alone from 0.29 to 0.46 after 24 h release (p < 0.05, t-test/two- 526
tailed). The improvement in bioactivity was again related to the 527
low water miscibility (see Section 3.3, microparticle characteriza- 528
tion); however, the low bioactive fractions for both formulations 529
indicated a high percentage of enzyme degradation during 530
preparation. 531
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Fig. 4. In vitro release of -CH from spray dried microparticles in aqueous 1% w/v  PLF68 medium, (A) microparticles prepared using DCM alone, CHF alone and different
concentrations of PLF68 in the internal phase (w1) of double emulsion, (B) microparticles prepared using CHF  alone and different concentrations PEG4500 in the internal
phase (w1) of double emulsion and (C) in vitro release of -CH and DNase I from microparticles prepared using CHF/PLF68, 1% in the internal phase (w1) of double emulsion
(data  represent mean ± SD, n = 3).
In this study the incorporation of PLF68 and PEG4500 in the532
internal aqueous phase (w1) not only improved the bioactivity533
(Perez and Griebenow, 2001), but was also shown to be concen-534
tration dependent, with low concentrations of PLF68 (1% w/v)535
(1.08 ± 0.07 at 0 h and 0.9 ± 0.02 at 24 h) and PEG4500 (1% w/v)536
(0.84 ± 0.08 at 0 h and 0.83 ± 0.02 at 24 h) enhancing the bioactiv-537
ity compared to the other formulations (p < 0.05, ANOVA/Tukey’s)538
(Table 2). This occurred due to the properties of PLF68 and PEG4500539
decreasing the surface tension of -CH solution, leading to reduced540
protein aggregation and adsorption to hydrophobic surfaces (Bilati541
et al., 2005; Blanco and Alonso, 1998). In addition, PEG4500 has542
the potential to prevent the dehydration-induced protein structural543
perturbations during the emulsiﬁcation process (Prestrelski et al.,544
1993). However, the reduced -CH bioactivity with increased PLF68545
(3.4% w/v) and PEG4500 (3.4 and 6.7% w/v) concentrations have546
been related to interactions with the enzyme resulting in its desta-547
bilization (Katakam et al., 1995). Furthermore, PLF68 (6.7% w/v) was548
not used due to separation of the w1/o emulsion and visual aggrega-549
tion of the enzyme. Due to [CHF/PLF68, 1%] and [CHF/PEG4500, 1%]550
maintaining the bioactive fraction of -CH more efﬁciently than the551
other formulations, they were carried forward for aerosolization552
performance and cell toxicity studies.553
3.5. In vitro aerosolisation performance554
The use of l-leucine as a dispersibility enhancer has been555
investigated in our research group (Tawfeek et al., 2011) and by556
others (Chew et al., 2005; Najafabadi et al., 2004) to enhance557
Table 2
The bioactive fraction of -CH released from different formulations at 0 h and after
24 h release in aqueous 1% w/v Pluronic® F68 medium, determined using the azo-
casein assay (data represent mean ± SD, n = 3).
Formulation Bioactive fraction at 0 h Bioactive fraction
after 24 h
DCM alone 0.29 ± 0.07 0.29 ± 0.06
CHF alone 0.46 ± 0.12* 0.46 ± 0.03*
CHF/PLF68, 1% 1.08 ± 0.07** 0.90 ± 0.02**
CHF/PLF68, 3.4% 0.63 ± 0.03 0.64 ± 0.05
CHF/PEG4500, 1% 0.84 ± 0.08** 0.83 ± 0.02**
CHF/PEG4500, 3.4% 0.75 ± 0.10 0.75 ± 0.03
CHF/PEG4500, 6.7% 0.63 ± 0.09 0.63 ± 0.07
* CHF alone vs DCM alone (p < 0.05, t-test/two-tailed).
** CHF/PLF68, 1% and CHF/PEG4500, 1% vs CHF alone (p < 0.05, ANOVA/Dunnett),
CHF/PLF68, 1% and CHF/PEG4500, 1% vs CHF/PLF68, 3.4%, CHF/PEG4500, 3.4%,
CHF/PEG4500, 6.7% (p < 0.05, ANOVA/Tukey’s).
the aerosolization performance. The deposition of -CH from 558
microparticles, [CHF/PLF68, 1%] and [CHF/PEG4500, 1%], in the 559
capsule, inhaler and mouthpiece is represented in Fig. 5A, 560
with no signiﬁcant difference after aerosolization (p > 0.05, t- 561
test/two-tailed). However, [CHF/PLF68, 1%)] microparticles had a 562
signiﬁcantly lower throat deposition compared to [CHF/PEG4500, 563
1%] (p < 0.05, t-test/two-tailed) (Fig. 5A). Both optimized micropar- 564
ticle formulations, [CHF/PLF68, 1%] and [CHF/PEG4500, 1%], 565
illustrated high deposition on stages 2–4 (cut-off diameter 566
4.6–1.6 m)  of the NGI, indicating these formulations would be 567
expected to deliver the majority of the emitted dose to the res- 568
pirable regions of the lung periphery, which is the target site for 569
CF patients (Westerman et al., 2007) (Fig. 5B) (p > 0.05, t-test/two- 570
tailed). 571
Table 3 represents the FPF (%), FPD (g) and MMAD (m)  572
of -CH loaded [CHF/PLF68, 1%] and [CHF/PEG4500, 1%] spray 573
dried microparticles, with signiﬁcant difference noted only in the 574
FPF (37.63 ± 0.97% and 33.69 ± 0.90%, respectively) (p < 0.05, t- 575
test/two-tailed). The theoretical aerodynamic diameters (Table 1) 576
calculated from tapped density indicate the suitability of PEG-co- 577
(PGA-co-PDL) microparticles for targeting the deep lungs, generally 578
≤1 m (Patton and Byron, 2007). However, the MMAD of the opti- 579
mum  formulations, [CHF/PLF68, 1%] and [CHF/PEG4500, 1%],  was 580
much larger at 2.95 and 2.75 m respectively, indicating deposition 581
in the lung periphery as noted above. This probably occurred due 582
to formation of particle aggregates during aerosolization, which 583
under the aerosolization parameters studied (ﬂow rate 60 L/s, using 584
the Handihaler) could not overcome van der Waals forces between 585
particles. 586
3.6. Cell viability study, proteolytic and mucinolytic activity 587
Spray dried microparticles (0–5 mg/ml) CHF alone (96.99 ± 8.70 588
to 80.01 ± 4.01% cell viability), [CHF/PLF68, 1%] (94.56 ± 6.20 to 589
86.57 ± 4.39% cell viability) and [CHF/PEG4500, 1%] (96.65 ± 3.43 to 590
88.16 ± 3.55% cell viability) appeared to be well tolerated by normal 591
Table 3
The aerosolization characteristics of spray dried -CH encapsulated microparticles
(data represent mean ± SD, n = 3).
Formulation FPF (%) FPD (g) MMAD  (m)
CHF/PLF68, 1% 37.63 ± 0.97* 179.88 ± 9.43 2.95 ± 1.61
CHF/PEG4500, 1% 33.69 ± 0.90 175.05 ± 3.57 2.75 ± 0.23
* CHF/PLF68, 1% vs CHF/PEG4500, 1% (p < 0.05, t-test/two-tailed).
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Fig. 5. Aerosol deposition of -CH from CHF/PLF68, 1% and CHF/PEG4500, 1%, (A) comparing the deposition of -CH in capsule, device, mouthpiece and throat, (B) the
deposition of -CH on different stages of NGI (data represents mean ± SD, n = 3). *CHF/PLF68, 1% vs CHF/PEG4500, 1% (p < 0.05, t-test/two-tailed).
lung bronchial epithelial cells (16HBE14o-) in vitro, even at high592
concentrations (5 mg/ml) following 24 h exposure, 80.01 ± 4.01,593
86.57 ± 4.39 and 88.16 ± 3.55% cell viability were obtained respec-594
tively. Consequently the tolerance of normal bronchial epithelial595
cells to high concentrations of microparticles provides an indi-596
cation to the feasibility of using PEG-co-(PGA-co-PDL) polymers597
as novel safe carriers for pulmonary delivery of -CH and other598
macromolecules.599
As there was no signiﬁcant difference in cell toxicity and aerosol600
performance between [CHF/PLF68, 1%] and [CHF/PEG4500, 1%]601
microparticles, [CHF/PLF68, 1%] was chosen as the optimum for-602
mulation due to higher bioactive fraction, and released enzyme603
was subjected to further analysis at 0 h and after 24 h in 1%604
w/v PLF68 release medium using SDS-page gelatin-zymography605
(Fig. 6). It appeared that the bands obtained for -CH released from606
[CHF/PLF68, 1%] microparticles were similar to the bands of the607
native enzyme at 0 h and after 24 h incubation, indicating incorpo-608
ration of PLF68 (1% w/v), [CHF/PLF68, 1%], in the internal aqueous609
phase (w1) of the double emulsion retained the proteolytic activ-610
ity of -CH after preparation, processing and release (Fig. 6). In611
addition, comparable mucinolytic activity was observed for -CH612
released from [CHF/PLF68, 1%] microparticles and an equivalent613
concentration of native non-encapsulated enzyme incubated in614
aqueous 1% w/v PLF68 medium up to 5 h (p > 0.05, t-test/two-615
tailed), which was  lower than the native non-encapsulated enzyme616
after 24 h (p > 0.05, t-test/two-tailed) (Fig. 7). Gaskell et al. have617
previously reported using mucin as a substrate for enzymes having618
mucinolytic activity, as a reproducible, reliable spectrophotometric619
assay (Gaskell et al., 2010). In this method light is transmitted and620
not absorbed as in standard photometric assays due to the tur-621
bidity of the mucin suspension. The results of this assay coincide622
Fig. 6. SDS page-zymography of -CH released from (A, B) CHF/PLF68, 1% at 0 h and
after (D, E) 24 h compared to equal amounts of native, non-encapsulated enzyme,
at  (C) 0 h and after (F) 24 h incubation in aqueous 1% w/v  PLF68 medium at 37 ◦C.
Fig. 7. The mucinolytic activity of native -CH enzyme and encapsulated -CH
within optimum microparticle formulation CHF/PLF68, 1% obtained from the muci-
nolytic degradation spectroscopic assay of mucin (data represent mean ± SD, n = 6).
with the release data obtained from [CHF/PLF68, 1%] microparticles 623
with the burst release at time 0 h responsible for the initial higher 624
mucinolytic activity followed by a gradual reduction over 24 h as 625
the release concentration falls. Activity of DNase I was  analyzed by 626
monitoring DNA-methyl green degradation following release stud- 627
ies at 0 h and 24 h. The activity was  found to be 90.1 ± 4.5% and 628
81.9 ± 2.7% respectively, compared to unprocessed DNase I. 629
4. Conclusion 630
The ﬁndings from our investigations indicate that PEG-co-(PGA- 631
co-PDL) can be used successfully to encapsulate -CH, and possibly 632
other macromolecules, in biocompatible microparticles utilizing 633
a double emulsion/spray drying technique with a good yield, 634
encapsulation efﬁciency and aerosolization performance. More- 635
over, incorporation of PLF68 (1% w/v) in the internal aqueous phase 636
(w1) of the double emulsion prior to emulsiﬁcation/spray drying 637
can maintain the bioactivity of -CH and protect it from the harsh 638
preparation conditions. The burst phase can be reduced to below 639
40% by incorporation of PLF68 or PEG4500 in the internal aqueous 640
phase, and this is followed by gradual release over 5 h in vitro. 641
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